

Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

Date: April 17, 2023

To, Listing Operations BSE Limited, P J Towers, Dalal Street, Mumbai-400001, India To, Listing Department National Stock Exchange of India Limited, Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400051

Sub.: Submission of daily report in accordance with Regulation 18(i) of the SEBI (Buy-back of Securities) Regulations, 2018 ("Buy-back Regulations")

## Ref.: Buy-back of Equity Shares of Windlas Biotech Limited (the "Company")

Dear Sir(s),

Pursuant to provisions of Regulation 18(i) of the Buy-back Regulations, we hereby submit the daily report with respect to Equity Shares bought back by the Company on April 17, 2023:

| Name of the Broker(s)                                           | Number of Equity Shares Bought Back<br>on April 17, 2023 |       | Total Shares<br>Bought Back | Average Price of<br>Acquisition Rs.* |
|-----------------------------------------------------------------|----------------------------------------------------------|-------|-----------------------------|--------------------------------------|
|                                                                 | BSE                                                      | NSE   | -                           |                                      |
| SMC Global Securities Limited                                   | 0                                                        | 1,316 | 1,316                       | 249.85                               |
| Total (A)                                                       | 0                                                        | 1,316 | 1,316                       | 249.85                               |
| Cumulative Equity Shares bought                                 | 8,89,839                                                 |       |                             |                                      |
| Less: Quantity Closed Out Today (C)                             |                                                          |       |                             | Nil                                  |
| Quantity Closed Out as on Yesterday (D)                         |                                                          |       |                             | Nil                                  |
| Total Quantity closed out (C+D=E                                | Nil                                                      |       |                             |                                      |
| Total Equity Shares bought back as on 17.04.2023 (A) +(B) - (E) |                                                          |       |                             | 8,91,155                             |

Fund utilized for the Buy-back as on April 17, 2023:

| Particulars                                                                             | Amount in Rs.   |
|-----------------------------------------------------------------------------------------|-----------------|
| Total amount earmarked for the Buy-back (Excluding Transaction Cost)                    | 25,00,00,000.00 |
| Total amount utilized on Buy-back on April 17, 2023 (Excluding Transaction Cost)        | 3,28,796.10     |
| Cumulative amount utilized on Buy-back till April 17, 2023 (Excluding Transaction Cost) | 22,36,78,243.30 |

## Windlas Biotech Limited



Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

## Notes:

- 1. \*Excludes Transaction Costs
- 2. Current reporting period is the day on which this report is being filed with the stock exchanges.
- 3. The above information is subject to settlement as per the existing rules for secondary market transactions of the Stock Exchanges and verification of Equity Shares bought back, where applicable.
- 4. For the purpose of this disclosure, 'Yesterday' shall refer to the last trading day.

Please acknowledge the receipt and inform the members of the Exchange.

For Windlas Biotech Limited

Ananta Narayan Panda Company Secretary & Compliance Officer